SIRION Biotech, the leading German viral vector company, will present a Webinar on November 17 at 2 PM GMT discussing optimizing lentivirus vector design for improved quality and safety
Optimizing the safety of lentiviral vectors has been one of the main focal points of lentiviral vector development. Likewise, the design of the lentiviral backbone and the therapeutic payload cassette can influence the manufacturability of the particles, for example their quality and potency features. Optimizing those features will further improve the safety and efficacy profile of future ex vivo and in vivo gene therapies.
To date the safety of over 25 lentivirus backbones has been tested in more than 200 clinical trials. SIRION Biotech will discuss the main features of those backbones and the main strategies to further optimize their safety. We will also give insights into datasets from our Viral Vector Know-How Hub to illustrate how payload design strategies can affect the manufacturability of the lentiviral particles and their usage to develop ex vivo and in vivo gene therapies. Our Viral Vector Know-How Hub includes data derived from over 6,000 lentiviral vectors.
We will also present a complementary strategy to optimize cell transduction by using LentiBOOST®, a chemical transduction enhancer currently used in more than 20 Phase I/II and III clinical trials, as part of developing a cGMP-compliant process to manufacture CD19-CAR T cells.
For more information about the Webinar, and to sign up to attend, please visit https://www.sirion-biotech.com/...
Optimizing the safety of lentiviral vectors has been one of the main focal points of lentiviral vector development. Likewise, the design of the lentiviral backbone and the therapeutic payload cassette can influence the manufacturability of the particles, for example their quality and potency features. Optimizing those features will further improve the safety and efficacy profile of future ex vivo and in vivo gene therapies.
To date the safety of over 25 lentivirus backbones has been tested in more than 200 clinical trials. SIRION Biotech will discuss the main features of those backbones and the main strategies to further optimize their safety. We will also give insights into datasets from our Viral Vector Know-How Hub to illustrate how payload design strategies can affect the manufacturability of the lentiviral particles and their usage to develop ex vivo and in vivo gene therapies. Our Viral Vector Know-How Hub includes data derived from over 6,000 lentiviral vectors.
We will also present a complementary strategy to optimize cell transduction by using LentiBOOST®, a chemical transduction enhancer currently used in more than 20 Phase I/II and III clinical trials, as part of developing a cGMP-compliant process to manufacture CD19-CAR T cells.
For more information about the Webinar, and to sign up to attend, please visit https://www.sirion-biotech.com/...
